CEO Corner articles are written by presidents or CEOs of biopharmaceutical or medical device companies that create a drug or device. These articles discuss global industry trends, experiences, and challenges that biopharma CEOs and presidents can relate to and should be aware of.
Like an ocean liner changing course, the national discussion around “modern” healthcare has moved slowly away from volume toward health outcomes. As such, we in the industry need to be both innovators and advocates for change.
“I’m often asked what it takes to be a successful biotech CEO, and as one of the relatively few female CEOs in our industry, what it takes to break the proverbial glass ceiling.”
Identifying and acquiring medicines would be relatively facile; however, convincing investors that the medicines were valuable was going to be a real challenge.
There are some key points for biotech companies to consider as they begin to transform their business model to one that captures the business continuum more fully.
Partnerships between pharmaceutical companies and patient advocacy groups hold the key to closing the rare-disease treatment gap. Their mutual commitment to improving patient care is the foundation for collaborative innovation in rare-disease education and research.
A diverse workplace is critical to building a successful biotech company. When you’re leading an organization working to bring life-saving drugs to the market, every second matters, and you need to attract and retain the best talent to be successful.
The CEO of Ovid Therapeutics, Jeremy Levin, feels no time has ever been better for biopharma leaders to speak out as part of their commitment to this industry.
Though biotechnology may never be as fast and efficient as software, we can make innovation and development faster — through nothing more than a Silicon-Valley way of thinking.
With gene therapy, we are at the dawn of another era of potentially rapid growth in the sector. And companies planning for their futures will once again consider a range of factors in identifying the optimal locations for gene therapy research and production centers.
All CEOs of small, publicly traded biotechs are required to wear many hats in the office every day. That’s why having a leader with a diverse background and experience in a variety of functional areas is an asset. Here we look at some of the various areas of expertise that can help create a more diverse C-suite executive.
Dr. Helen Torley, president and CEO of Halozyme Therapeutics, shares a story of how the biopharmaceutical industry makes a difference.
Halozyme Therapeutics’ president and CEO, Dr. Helen Torley, discusses her path to the c-suite, including the formative experience that best prepared her for becoming a CEO.
Helen Torley, president and CEO of Halozyme Therapeutics, discusses hyaluronan and the role it plays in development of ENHANZE, PEGPH20 along with a staining diagnostic to determine patients with high levels of hyaluronic acid (HA).
Rob Wright provides insight into The Board Meeting West, a life sciences industry event for high-level biopharmaceutical executives serving on corporate boards, or hoping to do so in the near future.
Rob Wright provides a bit of his perspective on the 37th Annual J.P. Morgan Healthcare Conference.